AVEO Pharmaceuticals is a commercial stage, oncology-focused biopharmaceutical company committed to delivering medicines for patients with cancer. Co.'s product candidates include: Tivozanib, which is for the treatment of renal cell carcinoma, hepatocellular carcinoma, immunologically cold tumors and cholangiocarcinoma; Ficlatuzumab, which is a humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor; AV-380, which is a humanized IgG1 monoclonal antibody that targets growth differentiation factor 15; AV-203, which is a humanized IgG1 monoclonal antibody that targets ErbB3; and AV-353, which is a IgG1 monoclonal antibody that targets the Notch 3 pathway.